Чарльз Эллис - Эпигенетика

EstellerM., Fraga M.F., Guo M., Garcia-Foncillas J., HedenfalkL, Godwin A.K., Trojan J., Vaurs-Barriere C., Bignon Y.J., Ramus S., et al., 2001b. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10: 3001-3007.

Fahmer J.A., Eguchi S., Herman J.G., and Baylin S.B., 2002. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62: 7213-7218.

Feinberg A.P. and Vogelstein B., 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.

Feinberg A.P., Gehrke C.W., Kuo K.C., and Ehrlich M., 1988. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48: 1159-1161.

Finch P.W., He X.. Kelley M.J., Uren A.. Schaudies R.P., Popescu N.C., Rudikoff S., Aaronson S.A., Varmus H.E., and Rubin J.S., 1997. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl. Acad. Sci. 94: 6770-6775.

Flatau E., Bogenmann E., and Jones P.A., 1983. Variable 5-methylcy-tosine levels in human tumor cell lines and fresh pediatric tumor explants. Cancer Res. 43: 4901-4905.

Frost P., Liteplo R.G., Donaghue T.P., and Kerbel R.S., 1984. Selection of strongly immunogenic “turn” variants from tumors at high frequency using 5-azacytidine. J. Exp. Med. 159: 1491-1501.

Fuks E., Hurd P.J., Deplus R., and Kouzarides T., 2003. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31: 2305-2312.

Fuks E., Burgers W.A., Godin N., Kasai M., and KouzaridesT., 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J., 20: 2536-2544.

Gaudet E., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., GrayJ.W, Leonhardt H., and Jaenisch R., 2003. Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492.

Gazzoli I., Loda M., Garber J., Syngal S., and Kolodner R.D., 2002. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62: 3925-3928.

Grady W.M., Wilis J., Guilford P.J., Dunbier A.K., Toro T.T., Lynch H., Wesner G., Ferguson K., Eng C, Park J.G., et al., 2000. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet. 26: 16-17.

Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C., 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.

Gregorieff A. and Clevers H., 2005. Wnt signaling in the intestinal epithelium: From endoderm to cancer. Genes Dev., 19: 877-890.

Hanahan D. and Weinberg R.A., 2000. The hallmarks of cancer. Cell 100: 57-70.

Herman J.G. and Baylin S.B., 2003. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med . 349: 2042-2054.

Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., Markowitz S., Wilson J.K., Hamilton S.R., Kinzler K.W, et al., 1998. Incidence and functional consequences of hMLHl promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci 95: 6870-6875.

Holm T.M., Jackson-Grusby L., BrambrinkT., Yamada Y, Rideout W.M., III, and Jaenisch R., 2005. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8: 275-285.

Holst C.R., Nuovo G.J., Esteller M., Chew K., Baylin S.B., Herman J.G., and Tlsty T. D., 2003. Methylation of plG lNK4a promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63: 1596-1601.

Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al., 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.

Issa J.P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., and Baylin S.B., 1994. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon Nat. Genet. 7: 536-540.

Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., Bayar E., Lyons J., Rosenfeld C.S., Cortes J., and Kantaijian H.M. 2004. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.

Jones P.A., 1999. The DNA methylation paradox. Trends Genet. 15: 34-37.

Jones PA. and Baylin S.B., 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.

Jones P.A. and Laird P.W, 1999. Cancer epigenetics comes of age. Nat. Genet. 21: 163-167.

Jones P.A. and Taylor S.M., 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell , 20: 85-93.

Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.-L., Leighton J.K., Patel H., Rahman A., Sridhara R., et al., 2005. Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11: 3604-3608.

Kaneda A. and Feinberg A.P., 2005. Loss of imprinting of IGF2: A common epigenetic modifier of intestinal tumor risk. Cancer Res. 65: 11236-11240.

Katzenellenbogen R.A., Baylin S.B., and Herman J.G., 1999. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-4353.

Kinzler K.W. and Vogelstein B., 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761-763.

Kiyono T, Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J., 1998. Both Rb/pl6 INK4ainactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.

Knudson A.G., 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157-162.

Kondo Y., Shen L., and Issa J.R, 2003. Critical role ofhistone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell. Biol. 23: 206-215.

Kuzmichev A., Margueron R., Vaquero A., PreissnerT.S., Scher M., KirmizisA., OuyangX., BrockdorffN., Abate-ShenC., Famham P., and Reinberg D., 2005. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. 102: 1859-1864.

Laird P.W., 2003. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3: 253-266.

Laird P.W., Jackson-Grusby L., Fazeli A., Dickinson S.L., Jung W.E., Li E., Weinberg R.A., and Jaenisch R., 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197-205.

Lapeyre J.N. and Becker F.F., 1979. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem. Biophys. Res. Commun. 87: 698-705.

Lee W.H., Morton R.A., Epstein J.I., Brooks J.D., Campbell P.A., Bova G.S., Hsieh W.S., Isaacs W.B., and Nelson W.G., 1994. Cytidine methylation of regulatory sequences near the xu-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. 91: 11733-11737.

Leu Y.W., Rahmatpanah F., Shi H., Wei S.H., Liu J.C., Yan P.S., and Huang T.H., 2003. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 63: 6110-6115.

Li E., Bestor T.H., and Jaenisch R., 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926.

Liu B., Nicolaides N.C., Markowitz S., Willson J.K., Parsons R.E., Jen J., Papadopolous N., Peltomaki P., de la Chapelle A., Hamilton S.R., et al., 1995. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 9: 48-55.

Lubbert M., 2000. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 249: 135-164.

Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K., 2001. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 1: 194-202.

Mizuno K., Osada H., Konishi H., Tatematsu Y., Yatabe Y., Mitsu-domi T., Fujii Y., and Takahashi T., 2002. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21: 2328-2333.

Morin P.J., Sparks A.B., KorinekV., Barker N., Clevers H., Vogelstein B., and Kinzler K.W., 1997. Activation of p-catenin-Tcf signaling in colon cancer by mutations in p-catenin or APC Science 275: 1787-1790.

Narayan A., Ji W., Zhang X.Y., Marrogi A., Graff J.R., Baylin S.B., and Ehrlich M., 1998. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer 77: 833-838.

Nemoto S., Fergusson M.M., and Finkel T., 2004. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105-2108.

Nguyen C.T., Gonzales F.A., and Jones P.A., 2001. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: Correlation of accessibility, methylation, MeCP2 binding and acetylation Nucleic Acids Res. 29: 4598-4606.

Pfeifer G.P., Tang M., and Denissenko M.F., 2000. Mutation hotspots and DNA methylation. Curr. Top. Microbiol. Immunol. 249: 1-19.

Rainier S., Johnson L.A., Dobry C.J., Ping A.J., Grundy P.E., and Feinberg A.P., 1993. Relaxation of imprinted genes in human cancer. Nature 362: 747-749.

Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., et al., 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.

Rhee I., Jair K.W., Yen R.W., Lengauer C., Herman J.G., Kinzler K.W., Vogelstein B., Baylin S.B., and Schuebel K.E., 2000. CpG methylation is mamtained in human cancer cells lacking DNMT1. Nature 404: 1003-1007.

Richon V.M. and O’Brien J.P., 2002. Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8: 662-664.

Rideout W.M., III, Coetzee G.A., Olumi A.F., and Jones P.A., 1990. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249: 1288-1290.

Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., and Wolffe A.P., 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25: 338-342.